March 22, 2024Cancer Research

PROTAC Degrader RP03707 Selectively Inhibits KRAS G12D Mutant Tumors

View Full Paper

Ask AI

Bookmark

The PROTAC degrader RP03707 efficiently degrades KRAS G12D oncoprotein and suppresses tumor growth across multiple mutant cancer models.
RP03707 eliminates over 90% of KRAS G12D protein within 24 hours in AsPc-1 cells and maintains 90% reduction for 7 days in GP2d mouse xenografts.
In vitro assays and mouse xenograft models demonstrate suppressed MAPK signaling and tumor regression; mouse model, further preclinical work needed.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates potent KRAS G12D degradation and tumor suppression in cell and mouse models, highlighting RP03707 as a viable cancer therapeutic.

Cite This Study

Ji et al. (2024) studied this question.

synapsesocial.com/papers/68e72bb1b6db6435876a5ff2 https://doi.org/10.1158/1538-7445.am2024-6050

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates potent KRAS G12D degradation and tumor suppression in cell and mouse models, highlighting RP03707 as a viable cancer therapeutic.

PROTAC Degrader RP03707 Selectively Inhibits KRAS G12D Mutant Tumors

Key Points

Discussion

Implication

Cite This Study

PROTAC Degrader RP03707 Selectively Inhibits KRAS G12D Mutant Tumors

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider